
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 11 |
| Oligonucleotide | 1 |
| CAR-T | 1 |
Target |
Mechanism PIAS2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism E2F1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MAO-A inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2026 |
Sponsor / Collaborator |
Start Date01 Feb 2026 |
Sponsor / Collaborator |
Start Date01 Nov 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
LN-1-255 ( β-lactamase ) | Bacterial Infections More | Preclinical |
CD19/huLym-1 DAP | Depressive Disorder More | Preclinical |
Compound 20(USC) ( MAO-A ) | Depressive Disorder More | Preclinical |
Compound 9(USC) ( MAO-A ) | Depressive Disorder More | Preclinical |
ISAM-CG557 ( CB2 ) | Neurodegenerative Diseases More | Preclinical |





